Gefitinib News and Research

RSS
Gefitinib is approved by the Food and Drug Administration (FDA) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not gotten better after treatment with other chemotherapy. It is available only as part of a special program called the Iressa Access Program. Gefitinib is also being studied in the treatment of other types of cancer.

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
AVEO reports total revenue of $133.6 million for first quarter 2011

AVEO reports total revenue of $133.6 million for first quarter 2011

Erlotinib, Gefitinib effective in treating certain subset of advanced NSCLC patients

Erlotinib, Gefitinib effective in treating certain subset of advanced NSCLC patients

AVEO receives USAN, WHO generic name approval for ficlatuzumab

AVEO receives USAN, WHO generic name approval for ficlatuzumab

AstraZeneca and Pfizer support Cancer Research UK in £5.5m Stratified Medicine programme

AstraZeneca and Pfizer support Cancer Research UK in £5.5m Stratified Medicine programme

Scientists find way to prevent early stage pancreatic cancer in research models

Scientists find way to prevent early stage pancreatic cancer in research models

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Targeted therapies could treat a broad range of cancers: Research

Targeted therapies could treat a broad range of cancers: Research

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Study: EGFR inhibtion may help treat triple negative breast cancer

Study: EGFR inhibtion may help treat triple negative breast cancer

Gefitinib exhibits potential as chemoprevention agent for pancreatic cancer

Gefitinib exhibits potential as chemoprevention agent for pancreatic cancer

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO third quarter total collaboration revenues increase to $6.2 million

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

New phase 2 study shows first-line promise of lung cancer drug PF-299

New phase 2 study shows first-line promise of lung cancer drug PF-299

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

Final results from landmark trial confirm survival benefits of EGFR mutations in lung cancer

Final results from landmark trial confirm survival benefits of EGFR mutations in lung cancer

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

First-line treatment with erlotinib drug improves progression-free survival in patients with advanced lung cancer

First-line treatment with erlotinib drug improves progression-free survival in patients with advanced lung cancer

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.